Is There an Association between Exposure to Environmental Estrogens and Breast Cancer?

Stephen H. Safe

Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas

It was initially reported that levels of polychlorinated biphenyls (PCBs) or p,p' DDE were elevated in breast cancer patients (serum or tissue) versus controls. These results, coupled with reports that selected environmental estrogens decreased 17β-estradiol (E2) 2-hydroxylase activity and increased the ratio of 16α-hydroxyestrone/2-hydroxyestrone metabolites in MCF-7 human breast cancer cells, have led to the hypothesis that xenestrogens are a preventable cause of breast cancer. More recent studies and analysis of organochlorine levels in breast cancer patients versus controls show that these contaminants are not elevated in the latter group. Moreover, occupational exposure to relatively high levels of PCBs and DDT/DDE are not associated with an increased incidence of breast cancer. A reexamination of the radiometric E2 2-hydroxylase assay in MCF-7 cells with diverse estrogens, antiestrogens, and carcinogens showed that the mammary carcinogen benzo(a)pyrene induced this response and the antiestrogen ICI 164,384 decreased E2 2-hydroxylase activity. Thus, E2 2-hydroxylase activity and the 16α-hydroxyestrone/2-hydroxyestrone metabolite ratio in MCF-7 cells does not predict xenestrogens or mammary carcinogens. — Environ Health Perspect 105(Suppl 3):675-678 (1997)

Key words: organochlorines, estrogens, breast cancer, hydroxylase activity

Background

Several studies have shown that a number of industrial compounds exhibit estrogenic activity and these include various phenols and structurally diverse organochlorine environmental contaminants such as polychlorinated biphenyls (PCBs), hydroxylated PCBs, kepone, methoxychlor, DDT, DDE, and related compounds (1-7). Moreover, some of the persistent organochlorine environmental contaminants have been linked to reproductive failures in some wildlife species and in laboratory animal studies (8). These observations have led to the hypothesis that endocrine-disrupting environmental contaminants may be responsible for decreased male reproductive capacity in humans, including a possible worldwide decrease in male sperm counts over the past 50 years (9,10). Carlsen and co-workers (11) reported that metaanalysis of selected sperm count studies showed a precipitous decline and this was supported by reports from Paris, Sweden, and Scotland (12-14). However, recent studies have also reported that during the past 20 to 25 years, sperm counts in New York, Minnesota, California, Washington, and Toulouse, France, have remained constant (15-17). These results show remarkable regional variations in sperm counts with the current high values in New York being comparable to those previously reported in the 1950s through 1960s (18). These regional variations suggest that metaanalysis may not be appropriate for analysis of temporal trends in sperm counts; moreover, the variability in these trends suggests that decreased sperm counts may be a local/regional problem and not a global calamity. Another important component of the endocrine disruptor hypothesis is that xenestrogens may also play a role in the observed increased incidence of breast cancer in the United States and many other countries (19,20). The Workshop on Hormones, Hormone Metabolism, and Breast Cancer focused on several aspects of this question and this paper will address issues raised by some of the invited speakers.

Role of Organochlorine Xenoestrogens in Breast Cancer

Several studies have demonstrated that the overall cumulative exposure of women to estrogens results in an increased risk for breast cancer. Some of these risk factors include age at menarche, age at first birth, age at natural menopause, parity, and obesity (postmenopausal) (21). Dietary and lifestyle factors also play a role in development of breast cancer and this is supported, in part, by the increased incidence of this disease in Oriental women (low incidence) who migrate to the United States. Davis and co-workers (19,20) have also hypothesized that changes in exposures to xenoestrogenic substances may partly account for recent trends in breast cancer.

The potential role of organochlorine compounds as etiologic agents in breast cancer was suggested by results of case-control studies that showed that a) levels of DDT and related metabolites (primarily p,p'-DDE) were higher in serum or tumors of breast cancer patients versus controls (22); b) PCB levels were higher in mammary adipose tissue of breast cancer patients in Connecticut than in controls (23); c) DDE levels were higher in mammary adipose tissue of estrogen receptor-positive breast cancer patients compared to controls (24); and d) 18-hexachlorocyclohexane levels in tumors were higher than in controls (25). All of these studies contained 58 or fewer individuals in their patient groups. Krieger and co-workers (26) used a cohort of 150 breast cancer patients and 150 control subjects in California and showed that there was not a significant difference in serum organochlorine levels in the two groups. There are several ongoing studies that are investigating levels of organochlorine compounds in breast cancer patients and control groups; however, at present the following points should be considered:

- Analysis of all the available data indicates that organochlorine levels are not significantly higher in breast cancer patients than in controls (27-29). In their review of the data for breast and endometrial cancers, Adami and co-workers (29) stated that "available data do not indicate that organochlorines will play a role in the risk of these two cancers in any but the most unusual situation." The overall ratio of means (cases-controls) for DDE and PCBs in all the
studies were 1.08 and 1.03 and were not significantly elevated (29).

- Adami and co-workers (29) also reviewed the breast cancer incidence in women occupationally exposed to PCBs; their summary analysis reported an overall observed/expected ratio of 0.84, indicating that among women highly exposed to PCBs, there was not an increased incidence of breast cancer. Moreover, high exposure to DDT has not been associated with an increased risk of breast cancer (28,29).

- Wolff (30) recently pointed out that adipose tissue levels of DDT and related metabolites (and PCBs) have been declining since 1965 and similar decreases in breast milk DDE levels have been reported in Scandinavian countries (31). These declines correspond to the restricted use and ultimate ban of DDT in most industrialized countries, even though there is continued use of this pesticide for insect control in less-developed nations. Nevertheless, the marked decline in DDE levels and the parallel increased incidence of breast cancer does not support an etiologic role for DDT in this disease.

- Several studies have demonstrated the estrogenic activity of DDT and related compounds as well as some PCBs and hydroxylated PCBs in breast cancer cells and in the rodent uterus. However, it is also true that other persistent chlorinated pollutants including some PCB congeners, polychlorinated dibenzo-p-dioxins and dibenzo-p-dioxins, exhibit antiestrogenic activities in the same bioassay (32). Safe (33) has suggested that in terms of dietary intake of organochlorine pollutants, the overall intake of antiestrogen equivalents was greater than estrogen equivalents in the diet. This is an issue that should be further investigated. In their article hypothesizing that xenosterogens may play a role in breast cancer, Davis and co-workers (19) pointed out that DDT accelerated 2-acetamidophenanthrene-induced mammary gland tumors in the male Sprague-Dawley rat (34). This is not a widely used animal model or carcinogen for investigating development and growth of breast cancer in women. In contrast, they failed to point out a study by Silinskas and Okey (35), who used the 7,12-dimethylbenz[a]anthracene (DMBA) model to show that DDT protected against mammary tumor formation in female rats.

These results do not support the hypothesis that organochlorine xenosterogens are etiologic agents for breast cancer. However, the studies that have reported elevated levels of PCBs, DDE, and polychlorinated biphenyls (36) in breast cancer patients should be further investigated. Persistent halogenated aromatic compounds preferentially bioconcentrate in fatty tissue and these compounds may be a biomarker of important dietary factors that play a role in mammary carcinogenesis.

**Good and Bad Estrogens?**

Bradlow and co-workers (19,20,37) have hypothesized a possible role for the 2-hydroxy and 16a-hydroxy metabolites of 17β-estradiol (E2) and estrone (E1) in the development of breast cancer. 16a-Hydroxy-E2 levels were elevated in strains of mice susceptible to mammary cancer and levels were also elevated in breast cancer patients (38,39). Osborne and co-workers (40) also reported that E2 16a-hydrolyase activity was higher in mammary terminal duct lobular units from breast cancer patients than in patients undergoing reductive mammaplasty. Swaneck and Fishman (41) also reported that 16α-hydroxy-E1 covalently binds to the estrogen receptor (ER) in MCF-7 cells and suggested that this may play a role in malignant transformation of mammary tissue. In contrast, increased levels of E2 2-hydrolyase activity are associated with protection from mammary cancer in both animal models and in humans; moreover, 2-hydroxy-E2 is elevated in animal models and humans exposed to indole-3-carbinol (33C) and related compounds that are protective against mammary cancer (38,41-43). The concept of good (2-hydroxy-E1/E2) and bad (16α-hydroxy-E1/E2) estrogens was recently expanded by Bradlow and co-workers (37), who proposed that the 16α-hydroxy-E1/2-hydroxy-E1 metabolite ratio in MCF-7 cells treated with E2 (radiolabeled with [3H] at C-2 or C-16) was predictive for mammary carcinogens. The compounds used in their study included the following: 13C, an anticarcinogen; DMBA, a mammary carcinogen; atrazine, a putative estrogen that enhances time-to-tumor formation in one rat strain; and several organochlorine pesticides that were either weakly estrogenic or indirectly associated with elevated breast cancer levels in some studies (γ-hexachlorocyclohexane, 2,2',4,4',5-pentachlorobiphenyl, kepone, p,p'-DDE, p,p'-DDE, o,p'-DDT, o,p'-DDT, endosulfan-1, endosulfan-2, and p,p'-DDethane). Treatment of MCF-7 cells with 10 µM 13C increased 2-hydroxylation and decreased 16α-hydroxylation of E2, whereas DMBA, atrazine, and the organochlorine pesticides decreased E2 2-hydrolyase and increased 16α-hydrolyase activities using a radiometric assay procedure. The predictive value of these hydrolyase activities and their ratios presented some problems based on results of other studies and these are indicated below.

- The induction of CYP1A1-dependent E2 2-hydrolyase activity by 10 µM 13C is inconsistent with previous studies, which report that 13C induces CYP1A1 gene expression or immunoreactive protein at concentrations >125 µM (44,45).

- Recent studies in this laboratory show that 10 µM 13C acts as a partial aryl hydrocarbon receptor antagonist (45).

- Most of the organochlorine pesticides included in this study are not active as inducers in cancer cell lines and their activity as inducers or inhibitors of E2 16α- or 2-hydrolyase activity has not previously been reported.

Atrazine was included in the list of compounds due to its designation as an estrogenic compound (20); however, recent studies have shown that this compound is not estrogenic in several diagnostic bioassays including the E-SCREEN (7,46). Therefore, research in this laboratory (47) has re-investigated the effects of several model compounds as inducers of E2 2-hydrolyase activity in MCF-7 cells using the radiometric assay. The results obtained for 13C were similar to those reported by Bradlow and co-workers (37); namely, a 2- to 4-fold induction of E2 2-hydrolyase was observed 48 hr after treatment with 13C. However, E2 2-hydrolyase activity was also induced after treatment with 13C for only 2 hr, indicating that the induced response was due, in part, to an in vitro effect and not an induction response. Similar results were obtained for atrazine and DMBA which caused decreased E2 2-hydroxylation in MCF-7 cells after incubation for 2 or 48 hr. Moreover, it was also shown that benzo[a]pyrene, a mammary carcinogen, induced E2 2-hydrolyase activity and this was consistent with previous reports showing that this compound induced CYP1A1-dependent activity in MCF-7 cells (48). In contrast, two potent antiestrogens, ICI 164,384 and ICI 182,780, decreased E2 2-hydroxylation in MCF-7 cells after incubation for 48 hr. These results indicate that a mammary carcinogen can induce E2 2-hydrolyase activity whereas this response
is inhibited by some antiestrogens that are anticarcinogens.

**Summary**

Although overall exposure to estrogens is a known risk factor for development of breast cancer, current data do not support a role of organochlorine compounds such as PCBs and DDE as etiologic agents. It is possible that there are other unknown sources of human exposure to xenoestrogens; however, their potential impact must be considered along with relatively high dietary intakes of natural estrogen (e.g., bioflavonoids) and antiestrogenic (e.g., isoflavones) substances in food (33). The results of recent studies in the laboratory suggest that the radiometric E2 2-hydroxylase activity in MCF-7 cells is not a consistent predictor of mammary carcinogens; however, this does not preclude the use of the 16α-hydroxy-E2/2-hydroxy-E2 ratio for predicting cancer risk in other in vitro or in vivo bioassays. The significance of 16α- and 2-hydroxy-E2/E1 metabolite ratios as prognostic indicators for mammary cancer is controversial (49) and also requires further investigation.

**REFERENCES**

1. Berthois Y, Karzenellenbogen JA, Karzenellenbogen BS. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83:2490–2500 (1986).

2. Krishnan AV, Stathis P, Permuth SF, Tokes L, Feldman D. Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. Endocrinology 132:2279–2286 (1993).

3. Korach KS, Sarver P, Chae K, McLachlan JA, McKinney JD. Estrogen receptor-binding activity of polychlorinated biphenyls: conformationally restricted structural probes. Mol Pharmacol 33:120–126 (1988).

4. Soto AM, Chung KL, Sonnenschein C. The pesticides endosulfan, toxaphene, and dieldrin have estrogenic effects on human estrogen-sensitive cells. Environ Health Perspect 102:380–383 (1994).

5. Soto AM, Justicia H, Wray JW, Sonnenschein C, P-Nonylphenol: an estrogenic xenobiotic released from "modified" polystyrene. Environ Health Perspect 92:167–173 (1991).

6. White R, Jobling S, Hoare SA, Sumpter JP, Parker MG. Environmentally persistent alkylphenolic compounds are estrogenic. Endocrinology 135:175–182 (1994).

7. Soto AM, Sonnenschein C, Chung KL, Fernandez MF, Olea N, Serrano FO. The E-screen assay as a tool to identify estrogens—an update on estrogenic environmental pollutants. Environ Health Perspect 103:113–122 (1995).

8. Colborn T, vom Saal FS, Soto AM. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect 101:378–384 (1993).

9. Sharpe RM, Skakkebaek NE. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet 341:1392–1395 (1993).

10. Sharpe RM. Reproductive biology. Another DDT connection. Environ Health Perspect 103:521–523 (1995).

11. Carlsten E, Giwercman A, Keiding N, Skakkebaek NE. Evidence for the decreasing quality of semen during the past 50 years. Br Med J 305:609–612 (1992).

12. Auger J, Kuntsmann JM, Czyglik F, Jouanet P. Decline in semen quality among fertile men in Paris during the past 20 years. N Engl J Med 332:281–285 (1985).

13. Bendvold E, Gottlieb C, Bygdeman M, Eneroth P. Depressed semen quality in Swedish men from barren couples: a study over three decades. Arch Androl 26:189–194 (1991).

14. Irvine S, Cawood E, Richardson D, MacDonald E, Aitken J. Evidence of deteriorating semen quality in the United Kingdom: birth cohort study in 577 men in Scotland over 11 years. Br Med J 312:467–471 (1996).

15. Fisch H, Goluboff ET, Olson JH, Feldshuh J, Broder SJ, Barad DH. Semen analyses in 1,283 men from the United States over a 25-year period: no decline in quality. Fertil Steril 65:1009–1014 (1996).

16. Paulsen CA, Bossert NG, Wang C. Data from men in greater Seattle area reveals no downward trend in semen quality: further evidence that deterioration of semen quality is not uniformly. Fertil Steril 65:1015–1020 (1996).

17. Bajan L, Mansat A, Pontonnier F, Miesus R. Time series analysis of sperm concentration in fertile men in Toulouse, France between 1977 and 1992. Br Med J 312:471–472 (1996).

18. Macleod J, Wang Y. Male fertility potential in terms of semen quality: a review of the past, a study of the present. Fertil Steril 31:103–116 (1979).

19. Davis DL, Bradlow HL, Wolff M, Woodruff T, Hoel DG, Anton-Culver H. Medical hypothesis: xenoestrogens as preventable causes of breast cancer. Environ Health Perspect 101:372–377 (1993).

20. Davis DL, Bradlow HL. Can environmental estrogens cause breast cancer. Sci Am 273:166–171 (1995).

21. Hulka BS, Liu ET, Lininge RA. Steroid hormones and risk of breast cancer. Cancer 74:1111–1124 (1994).

22. Wolff MS, Toniole PG, Lee EW, Rivera M, Dubin N. Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst 85:648–652 (1993).

23. Falck F, Ricci A, Wolff MS, Godbold J, Deckers P. Pesticides and polychlorinated biphenyl residues in human breast fluids and their relation to breast cancer. Arch Environ Health 47:143–146 (1992).

24. Dewaile Y, Dodin S, Verreaux R, Ayotte P, Sauvé L, Morin J, Brisson J. High organochlorine body burden in women with estrogen receptor-positive breast cancer. J Natl Cancer Inst 86:232–234 (1994).

25. Mussalo-Rahamaa H, Hääräinen E, Pyysalo H, Anttiroko K, Kauppila R, Panzar P. Occurrence of β-hexachlorocyclohexane in breast cancer patients. Cancer 66:2124–2128 (1990).

26. Krieger N, Wolff MS, Hiatt RA, Rivera M, Vogelmann J, Orentreich N. Breast cancer and serum organochlorines: a prospective study among white, black, and Asian women. J Natl Cancer Inst 86:589–599 (1994).

27. Key T, Reeves G. Organochlorines in the environment and breast cancer. Br Med J 308:1520–1521 (1994).

28. Ahlborg UG, Lipworth L, Titusensnoff L, Hsieh CC, Hanberg A, Baron J, Trichopoulos D, Adami HO. Organochlorine compounds in relation to breast cancer, endometrial cancer, and endometriosis: as assessment of the biological and epidemiological evidence. Crit Rev Toxicol 25:463–531 (1995).

29. Adami HO, Lipworth L, Titusensnoff L, Hsieh CC, Hanberg A, Ahlborg U, Baron J, Trichopoulos D. Organochlorine compounds and estrogen-related cancers in women. Cancer Causes Control 6:551–566 (1995).

30. Wolff MS. Pesticides—how research has succeeded and failed in informing policy: DDT and the link with breast cancer. Environ Health Perspect 103(Suppl 6):87–91 (1995).

31. Ekbom A, Wicklund-Glynn A, Adami HO. DDT and testicular cancer. Nature 347:553–554 (1996).

32. Safe S. Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo- p-dioxin and related compounds. Pharmacol Therap 67:247–281 (1995).

33. Safe S. Environmental and dietary estrogens and human health—is there a problem? Environ Health Perspect 103:346–351 (1995).
34. Scribner JD, Mottet NK. DDT acceleration of mammary gland tumors induced in the male Sprague-Dawley rat by 2-acetamidophenanthrene. Carcinogenesis 2:1235–1239 (1981).
35. Silinskas KC, Okey AB. Protection by 1,1,1-trichloro-2,2-bis(4-chlorophenyl)ethane (DDT) against mammary tumors and leukemia during prolonged feeding of 7,12-dimethylbenz(a)anthracene to female rats. J Natl Cancer Inst 55:653–657 (1975).
36. Henderson AK, Rosen D, Miller GL, Figgis LW, Zahm SH, Sieber SM, Humphrey HEB, Sinks T. Breast cancer among women exposed to polybrominated biphenyls. Epidemiology 6:544–546 (1995).
37. Bradlow HL, Davis DL, Lin G, Sepkovic D, Tiwari RK. The ratio of 16α/2-hydroxyestrone as a biologic marker of breast cancer risk. Environ Health Perspect 103:147–150 (1995).
38. Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, Fishman J. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA 79:3047–3051 (1982).
39. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J. Estradiol 16α-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci USA 82:6295–6299 (1985).
40. Osborne MP, Bradlow HL, Wong GY, Telang NT. Upregulation of estradiol C16 α-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J Natl Cancer Inst 85:1917–1920 (1993).
41. Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 85:7831–7835 (1988).
42. Bradlow HL, Michnovicz JJ, Telang NT, Osborne MP. Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12:1571–1574 (1991).
43. Grubbs CJ, Steele VE, Casebolt T, Juliana MM, Eto I, Whitaker LM, Dragnev KH, Kelloff GJ, Lubet RL. Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res 15:709–716 (1995).
44. Tiwari RK, Guo L, Bradlow HL, Telang NT, Osborne MP. Selective responsiveness of breast cancer cells to indole-3-carbinol, a chemopreventative agent. J Natl Cancer Inst 86:126–131 (1994).
45. Chen I, Safe S, Bjeldanes L. Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. Biochem Pharmacol 51:1069–1076 (1996).
46. Connor K, Howell J, Chen I, Liu H, Berhane K, Sciarretta C, Safe S, Zacharewski T. Failure of chloro-1,3-triazine-derived compounds to induce estrogen receptor-mediated responses in vivo and in vitro. Fundam Appl Toxicol 30:93–101 (1996).
47. McDougald A, Wilson C, Safe S. Unpublished data.
48. Chaloupka K, Krishnan V, Safe S. Polynuclear aromatic hydrocarbon carcinogens as antiestrogens in MCF-7 human breast cancer cells. Role of the Ah receptor. Carcinogenesis 13:2223–2239 (1992).
49. Aldercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT, Hämäläinen E. Estrogen metabolism and excretion in Oriental and Caucasian women. J Natl Cancer Inst 86:1076–1082 (1994).